# Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer

> **NCT03238495** · PHASE2 · UNKNOWN · sponsor: **Qamar Khan** · enrollment: 100 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Taxotere, Carboplatin, Herceptin + Pertuzumab
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT03238495
- **Lead sponsor:** Qamar Khan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-15
- **Primary completion:** 2022-06-01
- **Final completion:** 2023-06-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03238495

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03238495, "Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03238495. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*